Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 2.5% – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shot up 2.5% during trading on Monday . The company traded as high as $0.34 and last traded at $0.32. 48,039,653 shares changed hands during trading, a decline of 32% from the average session volume of 70,497,063 shares. The stock had previously closed at $0.31.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 1st. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Up 2.2 %

The company has a market cap of $59.21 million, a PE ratio of -0.01 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a fifty day simple moving average of $0.24 and a 200 day simple moving average of $0.35.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.